Sources last read 2026-08-17

The page

Where compounded GLP-1s and peptides come from

Name: FDA drug listings for GLP-1 and peptide compounds
Creator: HealthspanLedger
Published: 2026-08-17
License: https://creativecommons.org/licenses/by/4.0/

Compounded semaglutide starts as raw powder from a registered chemical supplier. FDA lists 577 registrations across the compounds on this site, and 473 of them are ingredient rather than finished medicine.

Source: FDA’s NDC directory and recall database, read 17 August 2026 and 17 August 2026

What matters first

Federal listings: 577
Ingredient listings: 473
Finished-product listings: 104
Recall events: 296

Two federal databases answer this. The NDC directory holds what companies have told FDA they sell. The enforcement database holds what has been pulled off the market. Neither is a quality ranking, and this page names no pharmacy — the counts and the reasons are the finding.

An NDC listing is a company telling FDA what it sells. It is not an FDA approval, an endorsement, or a quality check, and FDA does not verify what it is told.

A recall is about specific batches made by a named company, not about the drug itself. FDA publishes these; we have not checked any of these products ourselves.

FDA listings split by application-backed product and raw or unfinished ingredient. The eight largest listing counts among compounds tracked on this site. An NDC listing is a company filing, not FDA approval or a quality grade. Tirzepatide: 166 listings; 112 raw or unfinished; 54 application-backed. Semaglutide: 136 listings; 112 raw or unfinished; 24 application-backed. Liraglutide: 61 listings; 39 raw or unfinished; 22 application-backed. NAD+: 31 listings; 31 raw or unfinished; 0 application-backed. Sermorelin: 17 listings; 17 raw or unfinished; 0 application-backed. BPC-157: 16 listings; 16 raw or unfinished; 0 application-backed. Tesamorelin: 13 listings; 11 raw or unfinished; 2 application-backed. Retatrutide: 11 listings; 11 raw or unfinished; 0 application-backed. — The eight largest NDC listing counts in the tracked record, retrieved 2026-08-17. A directory entry is a company filing, not FDA approval or a quality grade.

Most of what FDA lists is not medicine

Every row below is a package a company registered with FDA. Registering is a filing, not an approval: FDA publishes what it was told and does not check it. The split that matters is the last two columns — a finished, approved product against raw active ingredient.

Listings in FDA’s NDC directory for each compound on this site, split by whether they are approved products or raw ingredient
Compound	Listings	Approved product	Raw ingredient	Companies
Tirzepatide	166	54	112	38
Semaglutide	136	24	112	49
Liraglutide	61	22	39	37
NAD+	31	0	31	25
Sermorelin	17	0	17	16
BPC-157	16	0	16	14
Tesamorelin	13	2	11	12
Retatrutide	11	0	11	6
Ipamorelin	10	0	10	10
TB-500	10	0	10	8
CJC-1295	9	0	9	9
MOTS-c	9	0	9	9
PT-141	9	1	8	9
Selank	9	0	9	9
Semax	9	0	9	9
Epitalon	8	0	8	8
Thymosin alpha-1	7	0	7	7
GHK-Cu	6	0	6	6
SS-31	6	1	5	6
DSIP	5	0	5	5
KPV	5	0	5	5
AOD-9604	4	0	4	4
Melanotan II	4	0	4	4
Kisspeptin-10	3	0	3	3
LL-37	3	0	3	3
Cagrilintide	2	0	2	2
Hexarelin	2	0	2	2
IGF-1 LR3	2	0	2	2
PEG-MGF	2	0	2	2
Pinealon	2	0	2	2

The peptides are the clearest case. BPC-157, retatrutide, MOTS-c, epitalon, KPV and the rest have no approved product in the directory at all — every listing against them is a supplier registering the powder. AHK-Cu, Mazdutide, Pemvidutide, Survodutide, VK2735, Zenagamtide has no listing of any kind, which is a fact about the registry rather than about the market.

Who registers the ingredient

These are the companies on the raw-ingredient listings, ordered by how many different compounds they register. Being here means a firm filed with FDA. It is not an approval, an inspection result or a recommendation, and nothing on this site links to any of them.

The fifteen companies registering the most distinct compounds as raw ingredient in FDA’s NDC directory
Registrant	Compounds	Listings	Includes
Qingdao Biopeptek Co., Ltd.	29	29	AOD-9604, BPC-157, CJC-1295, Cagrilintide
DARMERICA, LLC	25	26	BPC-157, CJC-1295, Epitalon, GHK-Cu
El-Peptido (Shanghai) Biopharmaceutical Co., Ltd	20	21	AOD-9604, BPC-157, CJC-1295, DSIP
Shenzhen Alvantis Pharma Co., Ltd.	19	21	AOD-9604, BPC-157, CJC-1295, Cagrilintide
Pure Peptide Pharmaceuticals Inc.	15	15	AOD-9604, BPC-157, CJC-1295, DSIP
SCH Global Services Private Limited	13	13	BPC-157, CJC-1295, Epitalon, MOTS-c
APISTER LIFESCIENCES PRIVATE LIMITED	9	9	BPC-157, DSIP, MOTS-c, NAD+
Hangzhou Pepsource Biomedical Co.,LTD	7	7	Epitalon, Ipamorelin, KPV, MOTS-c
Bills Biotech Pvt. Ltd.	5	5	Selank, Semaglutide, Semax, TB-500
Hangzhou Pepsource Biomedical Co., LTD	5	5	BPC-157, CJC-1295, PT-141, Selank
Hybio Pharmaceutical Co., Ltd. (Pingshan Factory)	4	21	Liraglutide, Retatrutide, Semaglutide, Tirzepatide
Fujian Genohope Biotech Ltd.	4	6	Liraglutide, NAD+, Semaglutide, Tirzepatide
Huzhou Huida New Material Co., Ltd.	4	4	BPC-157, CJC-1295, Ipamorelin, Tesamorelin
Pharma Source Direct, Inc.	4	4	NAD+, Semaglutide, Sermorelin, Tirzepatide
Zhejiang Wild Wind Pharmaceutical Co.,Ltd.	4	4	BPC-157, Ipamorelin, Sermorelin, Tesamorelin

What has been recalled, by compound

A recall covers named batches from one company. It is not a verdict on a substance, and a recall that FDA has closed was not a safe product — closing describes the paperwork. Sermorelin has been in FDA records the longest and has very few side-effect reports. Compare those records with the side-effect study.

296 distinct FDA recall events appeared across 306 tracked-search matches, including the glutathione class comparator. 10 events matched more than one tracked compound, so the downloadable table keeps one row per FDA recall number and lists every match on that row.

Recall records in FDA’s enforcement database for each compound on this site
Compound	Matched records	Companies	Most-used reason word
Sermorelin	92	27	sterility — 81 of 92
Semaglutide	43	16	sterility — 27 of 43
Tirzepatide	21	6	sterility — 12 of 21
Ipamorelin	18	8	sterility — 18 of 18
NAD+	16	9	sterility — 11 of 16
BPC-157	6	5	sterility — 6 of 6
CJC-1295	4	4	sterility — 4 of 4
Liraglutide	4	2	temperature — 3 of 4
PT-141	4	4	sterility — 4 of 4
TB-500	4	3	sterility — 4 of 4
Melanotan II	3	3	sterility — 3 of 3
AOD-9604	2	2	sterility — 2 of 2
Epitalon	2	2	sterility — 2 of 2
GHK-Cu	2	2	sterility — 2 of 2
IGF-1 LR3	2	1	sterility — 2 of 2
LL-37	2	2	sterility — 2 of 2
Tesamorelin	2	2	labeling — 1 of 2
DSIP	1	1	sterility — 1 of 1
Retatrutide	1	1	sterility — 1 of 1

17 of the compounds here have no recall record at all: AHK-Cu, Cagrilintide, Hexarelin, Kisspeptin-10, KPV, Mazdutide, MOTS-c, PEG-MGF, Pemvidutide, Pinealon, Selank, Semax, SS-31, Survodutide, Thymosin alpha-1, VK2735, Zenagamtide. That is not a clean bill of health. A seller that never registered with FDA cannot recall anything, because it never entered the system that produces recalls.

For scale, glutathione — not a peptide, and a staple of injectable compounding — carries 77 recall records from 45 companies. Sterility failures are a property of making injections in small batches, not of peptides.

6Inspect the underlying recordsRecall and listing drill-downs, vial arithmetic, limits, and related records

Semaglutide recalls in detail

FDA has published 43 recall records naming semaglutide, filed by 16 companies, checked 17 August 2026.

Hazard class and recall stage for Semaglutide, from FDA’s enforcement database
Hazard class	Records	What FDA means by it
Class II	43	Class II — FDA judged that using this product may cause temporary or medically reversible harm, and that serious harm is unlikely.
Ongoing	36	The recall is still running — the firm is still retrieving or correcting the product.
Completed	3	The firm has finished retrieving or correcting every unit it could reach.
Terminated	4	FDA has closed the recall. That is a statement about the process finishing, not about the product having been safe.

FDA writes its own reason on each record. These are its words, counted:

27 of 43 recall records naming semaglutide use the word “sterility”.
3 of 43 recall records naming semaglutide use the word “temperature”.
2 of 43 recall records naming semaglutide use the word “endotoxin”.
2 of 43 recall records naming semaglutide use the word “particulate”.

FDA matched 1 of 43 recall records naming semaglutide to an approved product listing. The other 42 name a preparation with no approved product behind it.

These are counts of recall filings, not of problems per batch made. Many small pharmacies file many small recalls; one large manufacturer files few large ones. Nobody publishes how many units either side made, so these counts cannot be read as which is safer.

16 companies filed these recalls. This site does not name pharmacies or outsourcing facilities. FDA does, on the page behind each recall number, and the newest here is D-0471-2026.

A recall is about specific batches made by a named company, not about the drug itself. FDA publishes these; we have not checked any of these products ourselves.

Each record covers named lot numbers from one company. It is not a statement about the substance in general.
The hazard class (Class I, II or III) is FDA’s judgment of risk. The status (Ongoing, Completed, Terminated) only says how far FDA is through the process — a terminated recall was not a safe product.
A recall means a problem was found and acted on. Products that were never checked produce no recalls at all.
FDA’s database is updated roughly weekly, so the date this was retrieved is part of the claim.
These are counts of recall filings, not of problems per batch made. Many small pharmacies file many small recalls; one large manufacturer files few large ones, and nobody publishes how much either side made.

Read 17 August 2026 from FDA’s recall database · US Government public domain · query product_description:("semaglutide")

Tirzepatide recalls in detail

FDA has published 21 recall records naming tirzepatide, filed by 6 companies, checked 17 August 2026.

Hazard class and recall stage for Tirzepatide, from FDA’s enforcement database
Hazard class	Records	What FDA means by it
Class I	1	Class I — FDA judged there is a reasonable probability that using this product will cause serious harm or death.
Class II	20	Class II — FDA judged that using this product may cause temporary or medically reversible harm, and that serious harm is unlikely.
Ongoing	21	The recall is still running — the firm is still retrieving or correcting the product.

FDA writes its own reason on each record. These are its words, counted:

12 of 21 recall records naming tirzepatide use the word “sterility”.
1 of 21 recall records naming tirzepatide use the word “labeling”.

FDA matched 0 of 21 recall records naming tirzepatide to an approved product listing. The other 21 name a preparation with no approved product behind it.

6 companies filed these recalls. This site does not name pharmacies or outsourcing facilities. FDA does, on the page behind each recall number, and the newest here is D-0394-2026.

A recall is about specific batches made by a named company, not about the drug itself. FDA publishes these; we have not checked any of these products ourselves.

Each record covers named lot numbers from one company. It is not a statement about the substance in general.
The hazard class (Class I, II or III) is FDA’s judgment of risk. The status (Ongoing, Completed, Terminated) only says how far FDA is through the process — a terminated recall was not a safe product.
A recall means a problem was found and acted on. Products that were never checked produce no recalls at all.
FDA’s database is updated roughly weekly, so the date this was retrieved is part of the claim.
These are counts of recall filings, not of problems per batch made. Many small pharmacies file many small recalls; one large manufacturer files few large ones, and nobody publishes how much either side made.

Read 17 August 2026 from FDA’s recall database · US Government public domain · query product_description:("tirzepatide")

Semaglutide listings in detail

FDA’s directory holds 136 semaglutide listings from 49 companies: 24 under an approved application and 112 registered as raw ingredient or an intermediate, checked 17 August 2026.

How the Semaglutide listings in FDA’s NDC directory divide by category
Category	Listings	What it means
Approved drug (NDA)	24	An approved new drug application. FDA reviewed this product and approved it.
Bulk active ingredient	55	Raw active ingredient, registered by the establishment that supplies it. It is not a finished medicine and FDA has approved nothing here.
Bulk ingredient for compounding	30	Raw active ingredient registered for use in compounding. Registering the ingredient is not permission to compound it — that is a separate question with its own rules.
Intermediate for further processing	27	An intermediate shipped to another manufacturer for further processing. Not a finished medicine and not sold to patients.

An NDC listing is a company telling FDA what it sells. It is not an FDA approval, an endorsement, or a quality check, and FDA does not verify what it is told.

Bulk ingredient means raw powder registered by a supplier. It is not a finished medicine, and no FDA review stands behind it.
Registering an ingredient with FDA is not permission to compound with it. Whether a substance may be compounded is a separate question with its own rules.
Every listing expires. A listing past its expiration date is not evidence of a product on sale today.
The labeler is the name on the box, which is not always the manufacturer. Repackagers list other companies’ products under their own name.
This is a dated snapshot of a directory FDA updates daily, not a live lookup.

Read 17 August 2026 from FDA’s NDC directory · US Government public domain · query generic_name:("semaglutide")

Who registers the raw ingredient, and what has been recalled, are on the compounded supply-chain record.

The concentrations these pens and vials actually hold

Every unit-conversion question depends on one number: milligrams per milliliter. FDA publishes it for each approved package, and these are its figures, with the NDC beside each one so you can look it up. A multi-dose Mounjaro vial holds 2.4 mL, so the same box covers four weekly doses.

Concentrations FDA lists for Mounjaro and Zepbound packages, with the package volume and NDC
Product	FDA strength	Per mL	In the package	NDC
Mounjaro	4.17 mg/mL	4.17 mg/mL	2.4 mL	0002-4052
Mounjaro KwikPen	4.17 mg/mL	4.17 mg/mL	2.4 mL	0002-3466
Mounjaro	2.5 mg/.5mL	5 mg/mL	0.5 mL	0002-1152
MOUNJARO	2.5 mg/.5mL	5 mg/mL	0.5 mL	50090-8025
Mounjaro	8.33 mg/mL	8.33 mg/mL	2.4 mL	0002-4103
Mounjaro KwikPen	8.33 mg/mL	8.33 mg/mL	2.4 mL	0002-3455
Mounjaro	5 mg/.5mL	10 mg/mL	0.5 mL	0002-1243
MOUNJARO	5 mg/.5mL	10 mg/mL	0.5 mL	50090-8024
Mounjaro	12.5 mg/mL	12.5 mg/mL	2.4 mL	0002-4210
Mounjaro KwikPen	12.5 mg/mL	12.5 mg/mL	2.4 mL	0002-3444
Mounjaro	7.5 mg/.5mL	15 mg/mL	0.5 mL	0002-1484
MOUNJARO	7.5 mg/.5mL	15 mg/mL	0.5 mL	50090-8023
Mounjaro	16.7 mg/mL	16.7 mg/mL	2.4 mL	0002-4304
Mounjaro KwikPen	16.7 mg/mL	16.7 mg/mL	2.4 mL	0002-3433
Mounjaro	10 mg/.5mL	20 mg/mL	0.5 mL	0002-1471
MOUNJARO	10 mg/.5mL	20 mg/mL	0.5 mL	50090-8021
Mounjaro	20.8 mg/mL	20.8 mg/mL	2.4 mL	0002-4523
Mounjaro KwikPen	20.8 mg/mL	20.8 mg/mL	2.4 mL	0002-3422
Mounjaro	12.5 mg/.5mL	25 mg/mL	0.5 mL	0002-1460
Mounjaro	25 mg/mL	25 mg/mL	2.4 mL	0002-4612
MOUNJARO	12.5 mg/.5mL	25 mg/mL	0.5 mL	50090-8022
Mounjaro KwikPen	25 mg/mL	25 mg/mL	2.4 mL	0002-3411
Mounjaro	15 mg/.5mL	30 mg/mL	0.5 mL	0002-1457
MOUNJARO	15 mg/.5mL	30 mg/mL	0.5 mL	50090-8026
Zepbound	4.17 mg/mL	4.17 mg/mL	2.4 mL	0002-6052
Zepbound KwikPen	4.17 mg/mL	4.17 mg/mL	2.4 mL	0002-3566
Zepbound	2.5 mg/.5mL	5 mg/mL	0.5 mL	0002-0152
ZEPBOUND	2.5 mg/.5mL	5 mg/mL	0.5 mL	0002-2506
Zepbound	8.33 mg/mL	8.33 mg/mL	2.4 mL	0002-6103
Zepbound KwikPen	8.33 mg/mL	8.33 mg/mL	2.4 mL	0002-3555
Zepbound	5 mg/.5mL	10 mg/mL	0.5 mL	0002-0243
ZEPBOUND	5 mg/.5mL	10 mg/mL	0.5 mL	0002-2495
Zepbound	12.5 mg/mL	12.5 mg/mL	2.4 mL	0002-6210
Zepbound KwikPen	12.5 mg/mL	12.5 mg/mL	2.4 mL	0002-3544
Zepbound	7.5 mg/.5mL	15 mg/mL	0.5 mL	0002-1214
ZEPBOUND	7.5 mg/.5mL	15 mg/mL	0.5 mL	0002-2484
Zepbound	16.7 mg/mL	16.7 mg/mL	2.4 mL	0002-6304
Zepbound KwikPen	16.7 mg/mL	16.7 mg/mL	2.4 mL	0002-3533
Zepbound	10 mg/.5mL	20 mg/mL	0.5 mL	0002-1340
ZEPBOUND	10 mg/.5mL	20 mg/mL	0.5 mL	0002-2471
Zepbound	20.8 mg/mL	20.8 mg/mL	2.4 mL	0002-6523
Zepbound KwikPen	20.8 mg/mL	20.8 mg/mL	2.4 mL	0002-3522
Zepbound	12.5 mg/.5mL	25 mg/mL	0.5 mL	0002-1423
Zepbound	25 mg/mL	25 mg/mL	2.4 mL	0002-6612
ZEPBOUND	12.5 mg/.5mL	25 mg/mL	0.5 mL	0002-2460
Zepbound KwikPen	25 mg/mL	25 mg/mL	2.4 mL	0002-3511
Zepbound	15 mg/.5mL	30 mg/mL	0.5 mL	0002-2002
ZEPBOUND	15 mg/.5mL	30 mg/mL	0.5 mL	0002-2457

These figures are what the reconstitution and unit calculators are checked against. The build fails if a package volume this site multiplies by stops appearing in FDA’s registry. It does not fail quietly and it does not correct itself: a person reads both sources and decides.

Where FDA’s registry disagrees with itself

One listing states two different volumes. The strength line and the packaging line do not match. We publish both rather than pick one.

0169-4517, WEGOVY: strength 1.7 mg/.75mL, packaging 0.5 mL.

What public records cannot tell you

A recall covers specific batches from one company; it does not prove that every compounded preparation is unsafe. Public records also cannot tell you what is inside a vial you already have.
Recall counts are counts of filings. Many small pharmacies file many small recalls; one large manufacturer files few large ones, and no one publishes how much either side made.
A company in the NDC directory has filed with FDA. It has not been approved, inspected on the strength of that filing, or endorsed, and registering an ingredient is not permission to compound it.
Neither database says anything about a seller that never registered. Those firms produce no listings and no recalls, and that silence is not a good sign.
The concentrations here are FDA’s figures for approved products. A compounded vial is mixed by a pharmacy and its concentration is whatever the label on it says.

How compounded GLP-1 drugs are regulated — the 503A and 503B rules, and the shortage test.
Compounded semaglutide, the FDA record — the determination, the deadlines and the dosing alert.
Compounded tirzepatide, the FDA record — the determination FDA made, withdrew and made again.
The dosing-error study — what people report after drawing a dose from a vial.

Questions people actually ask

Where does compounded semaglutide come from?

From raw semaglutide powder made by a registered chemical supplier, mixed into vials by a pharmacy or outsourcing facility. FDA’s directory shows the first half of that: FDA’s directory holds 136 semaglutide listings from 49 companies: 24 under an approved application and 112 registered as raw ingredient or an intermediate, checked 17 August 2026.

Does a listing in FDA’s directory mean FDA has approved it?

No. A listing is a company telling FDA what it sells. FDA publishes the filing and does not verify it. Only the approved categories — NDA, ANDA and BLA — mean FDA reviewed the product itself.

Have compounded GLP-1 drugs been recalled?

Yes, repeatedly, in named batches from named companies, and the stated reason is usually a lack of assurance of sterility. The counts and FDA’s own words are above. What that does not establish is a rate: nobody publishes how many batches were made.

Why does BPC-157 have recalls but almost no side-effect reports?

Because the two systems listen for different things. Side-effect reports arrive through prescribers, pharmacists and manufacturers of approved products, and BPC-157 has none. A compounding pharmacy is a registered establishment whatever it is mixing, so when a batch fails there is a recall record.

Why are so many ingredient suppliers based outside the US?

Because that is where peptide synthesis happens at scale. The table above shows what FDA’s registry says and nothing more — a registration is a filing, and it carries no judgment about the quality of what is shipped.

Take the listing table

One row per listing, with the labeler, FDA’s marketing category and FDA’s own flag for whether the listing is a medicine or raw ingredient.

The tallies above are all recomputable from it. Nothing in the file was read off a server-side count.

How to cite this table

HealthspanLedger. FDA drug listings for GLP-1 and peptide compounds. Edition 2026.08 (version 378fefb14c5f). Derived from openFDA National Drug Code directory, retrieved 2026-08-17. Licensed CC BY 4.0. https://healthspanledger.com/compounded/supply-chain

Analysis by HealthspanLedger · edition 2026.08 · version 378fefb14c5f · retrieved 2026-08-17

The underlying records are us government work, public domain and carry no copyright: the publisher’s own license. This table — how we select, join, label and bound the facts — is ours, and it is published under Creative Commons Attribution 4.0 International (CC BY 4.0). Reuse it, including commercially, and credit HealthspanLedger with a link to this page.

Take the recall table

One row per distinct FDA recall number, with every tracked search and compound match retained on that row. Hazard class and process status stay in separate columns, because they answer different questions.

A recall record is about a firm and a lot. It is not a verdict on a molecule.

How to cite this table

HealthspanLedger. FDA drug recall records for GLP-1 and peptide products. Edition 2026.08 (version 33d460f14b0e). Derived from openFDA drug enforcement (recall) database, retrieved 2026-08-17. Licensed CC BY 4.0. https://healthspanledger.com/compounded/supply-chain

Analysis by HealthspanLedger · edition 2026.08 · version 33d460f14b0e · retrieved 2026-08-17

Sources

FDA National Drug Code Directory — 577 listings across 36 compounds, via openFDA · US Food and Drug Administration · retrieved 2026-08-17
FDA drug recall enforcement reports — 37 search expressions, via openFDA · US Food and Drug Administration · retrieved 2026-08-17
openFDA data license — US Government public domain · US Food and Drug Administration · retrieved 2026-08-17

How we checked these details

Every count here is computed from a dated capture of FDA’s own data, committed to this repository and reviewable line by line. Each search expression is printed beside the figures it produced, so anyone can paste it into openFDA and get the same answer. No pharmacy, outsourcing facility or telehealth service is named, ranked or linked. Not legal advice, not a treatment recommendation. Corrections go to contact@healthspanledger.com.

Where compounded GLP-1s and peptides come from

What matters first

Most of what FDA lists is not medicine

Who registers the ingredient

What has been recalled, by compound

Semaglutide recalls in detail

Tirzepatide recalls in detail

Semaglutide listings in detail

The concentrations these pens and vials actually hold

Where FDA’s registry disagrees with itself

What public records cannot tell you

Keep reading

Questions people actually ask

Where does compounded semaglutide come from?

Does a listing in FDA’s directory mean FDA has approved it?

Have compounded GLP-1 drugs been recalled?

Why does BPC-157 have recalls but almost no side-effect reports?

Why are so many ingredient suppliers based outside the US?

Take the listing table

Take the recall table

Sources

How we checked these details